Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision

References

• Adamson SJ, Sellman JD, Foulds JA, Frampton CM, Deering D, Dunn A, Berks J, Nixon L, Cape G. 2015. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 35:143–149.
   Google Scholar
• Adcock RA, Thangavel A, Whitfield-Gabrieli S, Knutson B, Gabrieli JD. 2006. Reward-motivated learning: mesolimbic activation precedes memory formation. Neuron. 50:507–517.
   Google Scholar
• Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G, Ceccanti M. 1999. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res. 23:1596–1604.
   Google Scholar
• Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. 2000. Ability of baclofen in reducing alcohol craving and intake: II-preliminary clinical evidence. Alcohol Clin Exp Res. 24:67–71.
   Google Scholar
• Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. 2002. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 37:504–508.
   Google Scholar
• Addolorato G, Leggio L. 2010. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des. 16:2113–2117.
   Google Scholar
• Addolorato G, Leggio L, Cardone S, Ferrulli A, Gasbarrini G. 2009. Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol. 43:559–563.
   Google Scholar
• Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R. Baclofen Study Group. 2011. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 46:312–317.
   Google Scholar
• Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, et al. 2007. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 370:1915–1922.
   Google Scholar
• Agabio R, Colombo G. 2014. GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front Neurosci. 8:140.
   Google Scholar
• Agosti V, Levin FR. 2006. The effects of alcohol and drug dependence on the course of depression. Am J Addict. 15:71–75.
   Google Scholar
• Ait-Daoud N, Johnson BA, Prihoda TJ, Hargita ID. 2001. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology (Berl). 154:23–27.
   Google Scholar
• Ait-Daoud N, Malcolm RJ, Jr., Johnson BA. 2006. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav. 31:1628–1649.
   Google Scholar
• Albertson TE, Chenoweth J, Ford J, Owen K, Sutter ME. 2014. Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes? J Med Toxicol. 10:369–381.
   Google Scholar
• Amadoe G, Gazdar A. 1967. Sudden death durin disulfiram–alcohol reaction. Q J Stud Alcohol. 28:649–654.
   Google Scholar
• Ameisen O. 2005. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 40:147–150.
   Google Scholar
• Ameisen O. 2008. The end of my addiction. New York: Farrar, Straus and Giroux.
   Google Scholar
• Anton RF. 2008. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 9:655–658.
   Google Scholar
• Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. 2008. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 28:5–12.
   Google Scholar
• Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, Roberts JS. 2001. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol. 21:72–77.
   Google Scholar
• Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, et al. COMBINE Study Research Group. 2006. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 295:2003–2017.
   Google Scholar
• Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, et al. 2004. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 24:421–428.
   Google Scholar
• American Psychiatric Association 2013. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing.
   Google Scholar
• Awissi DK, Lebrun G, Coursin DB, Riker RR, Skrobik Y. 2013. Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary. Intensive Care Med. 39:16–30.
   Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, et al. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders: first revision. World J Biol Psychiatry. 9:248–312.
   Google Scholar
• Barrons R, Roberts N. 2010. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther. 35:153–167.
   Google Scholar
• Basavarajappa BS, Hungund BL. 2005. Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol Alcohol. 40:15–24.
   Google Scholar
• Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E. 2014. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 38:2169–2177.
   Google Scholar
• Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ. 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 14:334–385.
   Google Scholar
• Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ. 2015. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 16:76–95.
   Google Scholar
• Beck AT. 1993. Cognitive therapy: past, present, and future. J Consult Clin Psychol. 61:194–198.
   Google Scholar
• Bellamoli E, Manganotti P, Schwartz RP, Rimondo C, Gomma M, Serpelloni G. 2014. rTMS in the treatment of drug addiction: an update about human studies. Behav Neurol. 2014:815215.
   Google Scholar
• Bencherif B, Wand GS, McCaul ME, Kim YK, Ilgin N, Dannals RF, et al. 2004. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry. 55:255–262.
   Google Scholar
• Berglund M, Thelander S, Jonsson E. 2003. Treating alcohol and drug abuse: an evidence based review. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA.
   Google Scholar
• Berner MM, Habbig S, Harter M. 2004. [Quality of guidelines for the treatment of alcohol related disorders: a systematic review and content analysis]. Fortschritte Der Neurologie-Psychiatrie. 72:696–704.
   Google Scholar
• Besheer J, Frisbee S, Randall PA, Jaramillo AA, Masciello M. 2016. Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats. Neuropharmacology. 101:216–224.
   Google Scholar
• Bjorkquist SE, Isohanni M, Makela R, Malinen L. 1976. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 53:333–342.
   Google Scholar
• Blodgett JC, Del Re AC, Maisel NC, Finney JW. 2014. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 38:1481–1488.
   Google Scholar
• Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. 1999. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 32:107–109.
   Google Scholar
• Bonnet U, Lensing M, Specka M, Scherbaum N. 2011. Comparison of two oral symptom-triggered pharmacological inpatient treatments of acute alcohol withdrawal: clomethiazole vs. clonazepam. Alcohol Alcohol. 46:68–73.
   Google Scholar
• Bozikas V, Petrikis P, Gamvrula K, Savvidou I, Karavatos A. 2002. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 26:197–199.
   Google Scholar
• Brady KT, Myrick H, Henderson S, Coffey SF. 2002. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 67:323–330.
   Google Scholar
• Brathen G, Ben-Menachem E, Brodtkorb E, Galvin R, Garcia-Monco JC, Halasz P, Hillbom M, Leone MA, Young AB. EFNS Task Force on Diagnosis and Treatment of Alcohol-Related Seizures. 2005. EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force. Eur J Neurol. 12:575–581.
   Google Scholar
• Brathen G, Brodtkorb E, Helde G, Sand T, Bovim G. 1999. The diversity of seizures related to alcohol use. A study of consecutive patients. Eur J Neurol. 6:697–703.
   Google Scholar
• Brennan R, Van Hout MC. 2014. Gamma-hydroxybutyrate (GHB): a scoping review of pharmacology, toxicology, motives for use, and user groups. J Psychoactive Drugs. 46:243–251.
   Google Scholar
• Brown ES, Davila D, Nakamura A, Carmody TJ, Rush AJ, Lo A, Holmes T, Adinoff B, Caetano R, Swann AC, et al. 2014. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res. 38:2113–2118.
   Google Scholar
• Brown RA, Evans DM, Miller IW, Burgess ES, Mueller TI. 1997. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol. 65:715–726.
   Google Scholar
• Brunetti M, Di Tizio L, Dezi S, Pozzi G, Grandinetti P, Martinotti G. 2012. Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci. 16:1346–1354.
   Google Scholar
• Brust JC. 2014. Acute withdrawal: diagnosis and treatment. Handbook Clin Neurol. 125:123–131.
   Google Scholar
• Cano-Cebrian MJ, Zornoza-Sabina T, Guerri C, Polache A, Granero L. 2003. Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol. 368:324–327.
   Google Scholar
• Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ. 2004. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry. 61:264–272.
   Google Scholar
• Ceccanti M, Inghilleri M, Attilia ML, Raccah R, Fiore M, Zangen A. 2015. Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study. Can J Physiol Pharmacol. 93:283–290.
   Google Scholar
• Chambers RA, Krystal JH, Self DW. 2001. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 50:71–83.
   Google Scholar
• Childs E, Roche DJ, King AC, de Wit H. 2012. Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements. Alcohol Clin Exp Res. 36:906–914.
   Google Scholar
• Choi EA, Ki SW, Kim SE, Kim JW, Park JK. 2005. The efficacy and safety of topiramate in the treatment of alcohol withdrawal. J Korean Neuropsychiatr Assoc. 44:328–333.
   Google Scholar
• Ciccocioppo R, Martin-Fardon R, Weiss F. 2002. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behaviour by drug-associated stimuli in rats. Neuropsychopharmacology. 27:391–399.
   Google Scholar
• Ciraulo DA, Jaffe JH. 1981. Tricyclic antidepressants in the treatment of depression associated with alcoholism. J Clin Psychopharmacol. 1:146–150.
   Google Scholar
• COMBINE Study Research Group. 2003a. Testing combined pharmacotherapies and behavioural interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcoholism, Clinical and Experimental Research 27:1123–1131.
   Google Scholar
• COMBINE Study Research Group. 2003b. Testing combined pharmacotherapies and behavioural interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 27:1107–1122.
   Google Scholar
• Connor JP, Haber PS, Hall WD. 2015. Alcohol use disorders. Lancet. 387:988–998.
   Google Scholar
• Conway KP, Compton W, Stinson FS, Grant BF. 2006. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 67:247–257.
   Google Scholar
• Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A. 1997. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 54:700–705.
   Google Scholar
• Costa ET, Soto EE, Cardoso RA, Olivera DS, Valenzuela CF. 2000. Acute effects of ethanol on kainate receptors in cultured hippocampal neurons. Alcohol Clin Exp Res. 24:220–225.
   Google Scholar
• Covault J, Gelernter J, Hesselbrock V, Nellissery M, Kranzler HR. 2004. Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet Part B Neuropsychiatric Genet. 129B:104–109.
   Google Scholar
• Cowen MS, Chen F, Lawrence AJ. 2004. Neuropeptides: implications for alcoholism. J Neurochem. 89:273–285.
   Google Scholar
• Crowder TL, Ariwodola OJ, Weiner JL. 2002. Ethanol antagonizes kainate receptor-mediated inhibition of evoked GABA(A) inhibitory postsynaptic currents in the rat hippocampal CA1 region. J Pharmacol Exp Ther. 303:937–944.
   Google Scholar
• Crunelle CL, Miller ML, Booij J, van den Brink W. 2010. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol. 20:69–79.
   Google Scholar
• Crunelle CL, Schulz S, de Bruin K, Miller ML, van den Brink W, Booij J. 2011. Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats. Eur Neuropsychopharmacol 21:205–210.
   Google Scholar
• Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. 2004. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 20:1566–1576.
   Google Scholar
• Dai X, Thavundayil J, Gianoulakis C. 2005. Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism. Alcohol Clin Exp Res. 29:1965–1975.
   Google Scholar
• Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. 2013. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. Cochrane Database Syst Rev. 7:CD004033.
   Google Scholar
• De Sousa A. 2004. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol. 39:528–531.
   Google Scholar
• de Sousa A. 2005. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 40:545–548.
   Google Scholar
• De Sousa AA, De Sousa J, Kapoor H. 2008. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Substance Abuse Treat. 34:460–463.
   Google Scholar
• Dick DM, Edenberg HJ, Xuei X, Goate A, Kuperman S, Schuckit M, Crowe R, Smith TL, Porjesz B, Begleiter H, Foroud T. 2004. Association of GABRG3 with alcohol dependence. Alcohol Clin Exp Res. 28:4–9.
   Google Scholar
• Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. 2015. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 110:920–930.
   Google Scholar
• Dooley DJ, Mieske CA, Borosky SA. 2000. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 280:107–110.
   Google Scholar
• Drake RE, Xie H, McHugo GJ, Green AI. 2000. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bull. 26:441–449.
   Google Scholar
• Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, et al. 2006. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology. 183:394–403.
   Google Scholar
• Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, et al. 2004. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet. 74:705–714.
   Google Scholar
• EMA. 2010. Guideline on the development of medicinal products for the treatment of alcohol dependence. London: European Medicines Agency.
   Google Scholar
• EMA. Selincro (nalmefene): summary of product characteristics [Internet]. London: European Medicines Agency; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002583/WC500140255.pdf
   Google Scholar
• Erwin BL, Slaton RM. 2014. Varenicline in the treatment of alcohol use disorders. Ann Pharmacother. 48:1445–1455.
   Google Scholar
• Eyer F, Schreckenberg M, Hecht D, Adorjan K, Schuster T, Felgenhauer N, Pfab R, Strubel T, Zilker T. 2011. Carbamazepine and valproate as adjuncts in the treatment of alcohol withdrawal syndrome: a retrospective cohort study. Alcohol Alcohol. 46:177–184.
   Google Scholar
• Farook JM, Morrell DJ, Lewis B, Littleton JM, Barron S. 2007. Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol. 42:296–300.
   Google Scholar
• Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. 2006. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 41:321–327.
   Google Scholar
• Fehr C, Sander T, Tadic A, Lenzen KP, Anghelescu I, Klawe C, Dahmen N, Schmidt LG, Szegedi A. 2006. Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatric Genet. 16:9–17.
   Google Scholar
• Ferri M, Amato L, Davoli M. 2006. Alcoholics anonymous and other 12-step programmes for alcohol dependence. Cochrane Database Syst Rev. 3:CD005032.
   Google Scholar
• Foulds JA, Douglas Sellman J, Adamson SJ, Boden JM, Mulder RT, Joyce PR. 2015. Depression outcome in alcohol dependent patients: an evaluation of the role of independent and substance-induced depression and other predictors. J Affect Disord. 174:503–510.
   Google Scholar
• Franchitto N, Pelissier F, Lauque D, Simon N, Lancon C. 2014. Self-Intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 49:79–83.
   Google Scholar
• Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. 2011. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology. 215:655–663.
   Google Scholar
• Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. 1986. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 256:1449–1455.
   Google Scholar
• Gabriel KI, Cunningham CL. 2005. Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res. 29:75–80.
   Google Scholar
• Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa GL. 1992. Gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res. 16:673–676.
   Google Scholar
• Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. 2010. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 34:1849–1857.
   Google Scholar
• Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Vivitrex Study Group. 2005. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomised controlled trial. JAMA. 293:1617–1625.
   Google Scholar
• Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. 1999. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 281:1318–1325.
   Google Scholar
• Gelfand EV, Cannon CP. 2006. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Invest Drugs. 15:307–315.
   Google Scholar
• Gianoulakis C. 2004. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Topics Med Chem. 4:39–50.
   Google Scholar
• Gianoulakis C, Beliveau D, Angelogianni P, Meaney M, Thavundayil J, Tawar V, Dumas M. 1989. Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 45:1097–1109.
   Google Scholar
• Gianoulakis C, Krishnan B, Thavundayil J. 1996. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry. 53:250–257.
   Google Scholar
• Gibbs JW, 3rd., Sombati S, DeLorenzo RJ, Coulter DA. 2000. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 41(Suppl 1):S10–S16.
   Google Scholar
• Girardi P, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Masciolli F, Raccah RN, et al. 2015. Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: a comparison with standard treatment. World J Biol Psychiatry. 16:66–73.
   Google Scholar
• Glass IB. 1989a. Alcoholic hallucinosis: a psychiatric enigma-1. The development of an idea. Br J Addict. 84:29–41.
   Google Scholar
• Glass IB. 1989b. Alcoholic hallucinosis: a psychiatric enigma-2. Follow-up studies. Br J Addict. 84:151–164.
   Google Scholar
• Gowing LR, Ali RL, Allsop S, Marsden J, Turf EE, West R, Witton J. 2015. Global statistics on addictive behaviours: 2014 status report. Addiction. 110:904–919.
   Google Scholar
• Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. 2004. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 74:223–234.
   Google Scholar
• Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS. 2015. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 72:757–766.
   Google Scholar
• Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B. 2005. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 35:1747–1759.
   Google Scholar
• Green AI. 2005. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin. Psychiatry. 66(Suppl 6):21–26.
   Google Scholar
• Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. 2003. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia Res. 60:81–85.
   Google Scholar
• Green AI, Salomon MS, Brenner MJ, Rawlins K. 2002. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets. CNS Neurol Disord. 1:129–139.
   Google Scholar
• Gryder DS, Rogawski MA. 2003. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 23:7069–7074.
   Google Scholar
• Gual A, He Y, Torup L, van den Brink W, Mann K. 2013. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 23:1432–1442.
   Google Scholar
• Guardia J, Roncero C, Galan J, Gonzalvo B, Burguete T, Casas M. 2011. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addict Behav. 36:265–269.
   Google Scholar
• Hald J, Jacobsen E. 1948. A drug sensitizing the organism to ethyl alcohol. Lancet. 2:1001–1004.
   Google Scholar
• Hansen HC, Maschke M, Schuchardt V, Tiecks F. 2005. [Alcohol delirium]. In: Diener HC, Putzki N, Berlit P, editors. [Guidelines for Diagnosis and Therapy in Neurology]. New York: Stuttgart Thieme. p. 448–454.
   Google Scholar
• Hargreaves GA, McGregor IS. 2007. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcohol Clin Exp Res. 31:1900–1907.
   Google Scholar
• Harris BR, Gibson DA, Prendergast MA, Blanchard JA, Holley RC, Hart SR, Scotland RL, Foster TC, Pedigo NW, Littleton JM. 2003. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res. 27:1724–1735.
   Google Scholar
• Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller H-J. 2015. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 16:142–170.
   Google Scholar
• Hashimoto E, Tayama M, Ishikawa H, Yamamoto M, Saito T. 2015. Influence of comorbid alcohol use disorder on treatment response of depressive patients. J Neural Transm (Vienna). 122:301–306.
   Google Scholar
• Hasin DS, Stinson FS, Ogburn E, Grant BF. 2007. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 64:830–842.
   Google Scholar
• Hasin DS, Tsai WY, Endicott J, Mueller TI, Coryell W, Keller M. 1996. Five-year course of major depression: effects of comorbid alcoholism. J Affect Disord. 41:63–70.
   Google Scholar
• Hays JT, Croghan IT, Schroeder DR, Ebbert JO, Hurt RD. 2011. Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study. J Substance Abuse Treat. 40:102–107.
   Google Scholar
• Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, Dohmen BM, Braus DF, Schumann G, Machulla HJ, et al. 2005. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry. 62:57–64.
   Google Scholar
• Herremans SC, Baeken C, Vanderbruggen N, Vanderhasselt MA, Zeeuws D, Santermans L, De Raedt R. 2012. No influence of one right-sided prefrontal HF-rTMS session on alcohol craving in recently detoxified alcohol-dependent patients: results of a naturalistic study. Drug Alcohol Depend. 120:209–213.
   Google Scholar
• Hillbom M, Pieninkeroinen I, Leone M. 2003. Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. CNS Drugs. 17:1013–1030.
   Google Scholar
• Hillemacher T, Leggio L, Heberlein A. 2015. Investigational therapies for the pharmacological treatment of alcoholism. Expert Opin Invest Drugs. 24:17–30.
   Google Scholar
• Hoppner J, Broese T, Wendler L, Berger C, Thome J. 2011. Repetitive transcranial magnetic stimulation (rTMS) for treatment of alcohol dependence. World J Biol Psychiatry. 12(Suppl 1):57–62.
   Google Scholar
• Horwitz RI, Gottlieb LD, Kraus ML. 1989. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial. Arch Intern Med. 149:1089–1093.
   Google Scholar
• Hubbell CL, Abelson ML, Wild KD, Neuman R, Reid LD. 1988. Further studies of opioids and intake of sweetened alcoholic beverage. Alcohol. 5:141–146.
   Google Scholar
• Hubbell CL, Czirr SA, Hunter GA, Beaman CM, LeCann NC, Reid LD. 1986. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol. 3:39–54.
   Google Scholar
• Hughes JC, Cook CC. 1997. The efficacy of disulfiram: a review of outcome studies. Addiction. 92:381–395.
   Google Scholar
• Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. 2013. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 10:CD001088.
   Google Scholar
• Jarjour S, Bai L, Gianoulakis C. 2009. Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcohol Clin Exp Res. 33:1033–1043.
   Google Scholar
• Johnson BA, Ait-Daoud N. 2000. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology. 149:327–344.
   Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. 2003. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 361:1677–1685.
   Google Scholar
• Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD. 2011. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 168:265–275.
   Google Scholar
• Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. 2000. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients. A randomized controlled trial. JAMA. 284:963–971.
   Google Scholar
• Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, et al. 2007. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 298:1641–1651.
   Google Scholar
• Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud N, Li MD. 2013. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry. 170:1020–1031.
   Google Scholar
• Johnson BA, Swift RM, Addolorato G, Ciraulo DA, Myrick H. 2005. Safety and efficacy of GABAergic medications for treating alcoholism. Alcohol Clin Exp Res. 29:248–254.
   Google Scholar
• Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, et al. 2014. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 311:1889–1900.
   Google Scholar
• Jones JD, Comer SD, Kranzler HR. 2015. The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res. 39:391–402.
   Google Scholar
• Jordaan GP, Emsley R. 2014. Alcohol-induced psychotic disorder: a review. Metab Brain Dis. 29:231–243.
   Google Scholar
• Jordaan GP, Warwick JM, Nel DG, Hewlett R, Emsley R. 2012. Alcohol-induced psychotic disorder: brain perfusion and psychopathology-before and after anti-psychotic treatment. Metab Brain Dis. 27:67–77.
   Google Scholar
• Kaminski RM, Banerjee M, Rogawski MA. 2004. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 46:1097–1104.
   Google Scholar
• Kaner EF, Beyer F, Dickinson HO, Pienaar E, Campbell F, Schlesinger C, Heather N, Saunders J, Burnand B. 2007. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2:CD004148.
   Google Scholar
• Kapil V, Green JL, Le Mait MC, Wood DM, Dargan PI. 2014. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 78:190–191.
   Google Scholar
• Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, Kallio A, Mäkelä R. 2007. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res. 31:1179–1187.
   Google Scholar
• Keating GM. 2014. Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Invest. 34:63–80.
   Google Scholar
• Kenna GA, McGeary JE, Swift RM. 2004a. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health-Syst Pharm. 61:2272–2279.
   Google Scholar
• Kenna GA, McGeary JE, Swift RM. 2004b. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am J Health-Syst Pharm. 61:2380–2388.
   Google Scholar
• Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Vuittonet C, Fricchione S, Brickley M, Beaucage K, et al. 2014. Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study. Alcohol Clin Exp Res. 38:1567–1574.
   Google Scholar
• Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 62:617–627.
   Google Scholar
• Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. 1997. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 54:313–321.
   Google Scholar
• Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, Wiedemann K. 2003. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 60:92–99.
   Google Scholar
• Kishi T, Sevy S, Chekuri R, Correll CU. 2013. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry. 74:e642–6e654.
   Google Scholar
• Kleber HD, Weiss RD, Anton RF, Jr., George TP, Greenfield SF, Kosten TR, O'Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, et al. 2007. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 164:5–123.
   Google Scholar
• Klimas J, Tobin H, Field CA, O'Gorman CS, Glynn LG, Keenan E, Saunders J, Bury G, Dunne C. 2014. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev. 12:CD009269.
   Google Scholar
• Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, et al 2015. Zonisamide, topiramate, and levitiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 35:34–42.
   Google Scholar
• Knoch D, Gianotti LR, Pascual-Leone A, Treyer V, Regard M, Hohmann M, Brugger P. 2006. Disruption of right prefrontal cortex by low-frequency repetitive transcranial magnetic stimulation induces risk-taking behavior. J Neurosci. 26:6469–6472.
   Google Scholar
• Koob GF. 2003. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res. 27:232–243.
   Google Scholar
• Koob GF, Le Moal M. 2006. Neurobiology of addiction. London, Burlington (San Diego): Academic Press.
   Google Scholar
• Krampe H, Ehrenreich H. 2010. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Design. 16:2076–2090.
   Google Scholar
• Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Ruther E, Poser W, Ehrenreich H. 2006. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res. 30:86–95.
   Google Scholar
• Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R. 2003a. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 23:294–304.
   Google Scholar
• Kranzler HR, Armeli S, Tennen H, Covault J. 2013. 5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity. Addict Biol. 18:1024–1031.
   Google Scholar
• Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM. 2014a. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 171:445–452.
   Google Scholar
• Kranzler HR, Gelernter J, Anton RF, Arias AJ, Herman A, Zhao H, Burian L, Covault J. 2009. Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res. 33:925–930.
   Google Scholar
• Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, et al. 2006. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 26:13–20.
   Google Scholar
• Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C. 2003b. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res. 27:1150–1155.
   Google Scholar
• Kranzler HR, Wesson DR, Billot L. 2004. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 28:1051–1059.
   Google Scholar
• Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. 2014b. Posttreatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res. 38:3017–3023.
   Google Scholar
• Kraus ML, Gottlieb LD, Horwitz RI, Anscher M. 1985. Randomized clinical trial of atenolol in patients with alcohol withdrawal. New Engl J Med. 313:905–909.
   Google Scholar
• Kravitz AV, Tomasi D, LeBlanc KH, Baler R, Volkow ND, Bonci A, Ferre S. 2015. Cortico-striatal circuits: Novel therapeutic targets for substance use disorders. Brain Res. 1628:186–198.
   Google Scholar
• Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. 2007. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 31:604–611.
   Google Scholar
• Krupitsky EM, Rybakova KV, Kiselev AS, Alexeeva YV, Berntsev VA, Chekhlaty EI, Zubova EY, Popov YV, Neznanov NG. 2015. [Double blind placebo controlled randomised pilot clinical trial of baclofen (Baclosan(R)) for alcohol dependence]. Zh Nevrol Psikhiatrii Im S S Korsakova. 115:53–62.
   Google Scholar
• Krystal JH, Tabakoff B. 2002. Ethanol abuse, dependence, and withdrawal: neurobiology and clinical implications. In: Davis K, Charney D, Coyle JT, Nemeroff C, editors. Psychopharmacology: a fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins. p. 1425–1443.
   Google Scholar
• Kuhn J, Grundler TO, Bauer R, Huff W, Fischer AG, Lenartz D, Maarouf M, Bührle C, Klosterkötter J, Ullsperger M, Sturm V. 2011. Successful deep brain stimulation of the nucleus accumbens in severe alcohol dependence is associated with changed performance monitoring. Addict Biol. 16:620–623.
   Google Scholar
• Kuhn J, Lenartz D, Huff W, Lee S, Koulousakis A, Klosterkoetter J, Sturm V. 2007. Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: valuable therapeutic implications?. J Neurol Neurosurg Psychiatry. 78:1152–1153.
   Google Scholar
• Lappalainen J, Krupitsky E, Remizov M, Pchelina S, Taraskina A, Zvartau E, Somberg LK, Covault J, Kranzler HR, Krystal JH. 2005. Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res. 29:493–498.
   Google Scholar
• Laramee P, Kusel J, Leonard S, Aubin HJ, Francois C, Daeppen JB. 2013. The economic burden of alcohol dependence in Europe. Alcohol Alcohol. 48:259–269.
   Google Scholar
• Latt N, Dore G. 2014. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J. 44:911–915.
   Google Scholar
• Le Fauve CE, Litten RZ, Randall CL, Moak DH, Salloum IM, Green AI. 2004. Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity. Alcohol Clin Exp Res. 28:302–312.
   Google Scholar
• Leone M, Tonini C, Bogliun G, Monaco F, Mutani R, Bottacchi E, Gambaro P, Rocci E, Tassinari T, Cavestro C, Beghi E. 2002. Chronic alcohol use and first symptomatic epileptic seizures. J Neurol Neurosurg Psychiatry. 73:495–499.
   Google Scholar
• Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. 2015. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 49:897–906.
   Google Scholar
• Lheureux P, Askenasi R. 1991. Efficacy of flumazenil in acute alcohol intoxication: double blind placebo-controlled evaluation. Hum Exp Toxicol. 10:235–239.
   Google Scholar
• Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M. 2013. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend. 133:440–446.
   Google Scholar
• Lingford-Hughes AR, Welch S, Nutt DJ. 2004. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 18:293–335.
   Google Scholar
• Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. 2012. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol (Oxford). 26:899–952.
   Google Scholar
• Lingford-Hughes AR, Wilson SJ, Cunningham VJ, Feeney A, Stevenson B, Brooks DJ, Nutt DJ. 2005. GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. Psychopharmacology. 180:595–606.
   Google Scholar
• Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, et al. 2013. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 7:277–286.
   Google Scholar
• Littleton J. 1995. Acamprosate in alcohol dependence: how does it work? Addiction. 90:1179–1188.
   Google Scholar
• Liu J, Wang LN. 2015. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev. 4:CD008502.
   Google Scholar
• Longo LP, Campbell T, Hubatch S. 2002. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 21:55–64.
   Google Scholar
• Lui S, Terplan M, Smith EJ. 2008. Psychosocial interventions for women enrolled in alcohol treatment during pregnancy. Cochrane Database Syst Rev. 3:CD006753.
   Google Scholar
• Luigjes J, van den Brink W, Schuurman PR, Kuhn J, Denys D. 2015. Is deep brain stimulation a treatment option for addiction?. Addiction. 110:547–548.
   Google Scholar
• Lynch WJ, Bond C, Breslin FJ, Johnson BA. 2011. Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. Psychopharmacology. 217:3–12.
   Google Scholar
• Mackenbach JP, Kulhanova I, Bopp M, Borrell C, Deboosere P, Kovacs K, Looman CW, Leinsalu M, Makela P, Martikaninen P, et al. 2015. Inequalities in alcohol-related mortality in 17 European countries: a retrospective analysis of mortality registers. PLoS Med. 12:e1001909.
   Google Scholar
• Magill M, Ray LA. 2009. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 70:516–527.
   Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. 2013. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 108:275–293.
   Google Scholar
• Majumdar SK. 1991. Chlormethiazole: current status in the treatment of the acute ethanol withdrawal syndrome. Drug Alcohol Depend. 27:201–207.
   Google Scholar
• Malcolm R, Ballenger JC, Sturgis ET, Anton R. 1989. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 146:617–621.
   Google Scholar
• Malcolm R, Myrick H, Brady KT, Ballenger JC. 2001. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict. 10 Suppl:16–23.
   Google Scholar
• Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. 2002. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomised trial. J Gen Intern Med. 17:349–355.
   Google Scholar
• Malec TS, Malec EA, Dongier M. 1996. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res. 20:853–858.
   Google Scholar
• Mann K, Bladstrom A, Torup L, Gual A, van den Brink W. 2013a. Extending the treatment options in alcohol dependence: a randomised controlled study of as-needed nalmefene. Biol Psychiatry. 73:706–713.
   Google Scholar
• Mann K, Hoch E, Batra A. 2016a. S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen. Heidelberg, Germany: Springer.
   Google Scholar
• Mann K, Hoffmann S, Pawlak CR. 2016b. Does acamprosate really produce its anti-relapse effects via calcium? No support from the PREDICT study in human alcoholics. Neuropsychopharmacology. 41:659–660.
   Google Scholar
• Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Smolka MN, et al. 2013b. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 18:937–946.
   Google Scholar
• Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. 2006. A randomised, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 15:76–84.
   Google Scholar
• Marinelli PW, Bai L, Quirion R, Gianoulakis C. 2005. A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 29:1821–1828.
   Google Scholar
• Marinelli PW, Lam M, Bai L, Quirion R, Gianoulakis C. 2006. A microdialysis profile of dynorphin A(1-8) release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 30:982–990.
   Google Scholar
• Marinelli PW, Quirion R, Gianoulakis C. 2004. An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience. 127:777–784.
   Google Scholar
• Martens F, Koppel C, Ibe K, Wagemann A, Tenczer J. 1990. Clinical experience with the benzodiazepine antagonist flumazenil in suspected benzodiazepine or ethanol poisoning. J Toxicol Clin Toxicol. 28:341–356.
   Google Scholar
• Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Beradis D, Iasevoili F, Torrens M, Di Giannantonio M. 2016. Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opin Investig Drugs. 25:719–728.
   Google Scholar
• Mason BJ, Goodman AM, Chabac S, Lehert P. 2006. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatric Res. 40:383–393.
   Google Scholar
• Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. 2014. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Inter Med. 174:70–77.
   Google Scholar
• Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. 1999. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 56:719–724.
   Google Scholar
• Mayo-Smith MF. 1997. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 278:144–151.
   Google Scholar
• Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, et al. 2004. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 164:1405–1412.
   Google Scholar
• McDonough M, Kennedy N, Glasper A, Bearn J. 2004. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 75:3–9.
   Google Scholar
• McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM. 1996. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 53:232–240.
   Google Scholar
• McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E. 2009. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 66:185–190.
   Google Scholar
• McQueen J, Howe TE, Allan L, Mains D. 2009. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. CD005191.
   Google Scholar
• Mersfelder TL, Nichols WH. 2016. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 50:229–233.
   Google Scholar
• Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. 2013. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. J Clin Psychopharmacol. 33:243–247.
   Google Scholar
• Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. 2005. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Res. 80:33–43.
   Google Scholar
• Miranda R, Jr., MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C. 2008. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 32:489–497.
   Google Scholar
• Mishra BR, Nizamie SH, Das B, Praharaj SK. 2010. Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study. Addiction. 105:49–55.
   Google Scholar
• Mishra BR, Praharaj SK, Katshu MZ, Sarkar S, Nizamie SH. 2015. Comparison of anticraving efficacy of right and left repetitive transcranial magnetic stimulation in alcohol dependence: a randomized double-blind study. J Neuropsychiatry Clin Neurosci. 27:e54–5e59.
   Google Scholar
• Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. 2012. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology. 223:299–306.
   Google Scholar
• Moghaddam B, Bolinao ML. 1994. Biphasic effect of ethanol on extracellular accumulation of glutamate in the hippocampus and the nucleus accumbens. Neurosci Lett. 178:99–102.
   Google Scholar
• Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. 2015. Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia. J Nerv Mental Dis. 203:486–492.
   Google Scholar
• Moore CF, Lycas MD, Bond CW, Johnson BA, Lynch WJ. 2014. Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats. Exp Clin Psychopharmacol. 22:35–42.
   Google Scholar
• Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. 2014. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol.
   Google Scholar
• Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR. 1997. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 21:86–92.
   Google Scholar
• Muhonen LH, Lonnqvist J, Juva K, Alho H. 2008. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 69:392–399.
   Google Scholar
• Muller CA, Geisel O, Banas R, Heinz A. 2014. Current pharmacological treatment approaches for alcohol dependence. Expert Opin Pharmacother. 15:471–481.
   Google Scholar
• Muller CA, Geisel O, Pelz P, Higl V, Kruger J, Stickel A, Beck A, Wernecke K-D, Helweg R, Heinz A. 2015. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomised, placebo-controlled trial. Eur Neuropsychopharmacol. 25:1167–1177.
   Google Scholar
• Muller UJ, Sturm V, Voges J, Heinze HJ, Galazky I, Heldmann M, Scheich H, Bogerts B. 2009. Successful treatment of chronic resistant alcoholism by deep brain stimulation of nucleus accumbens: first experience with three cases. Pharmacopsychiatry. 42:288–291.
   Google Scholar
• Munster van BC, Korevaar JC, de Rooij SE, Levi M, Zwinderman AH. 2007. Genetic polymorphisms related to delirium tremens: a systematic review. Alcohol Clin Exp Res. 31:177–184.
   Google Scholar
• Mutschler J, Abbruzzese E, Witt SH, Dirican G, Nieratschker V, Frank J, Grosshans M, Rietschel M, Kiefer F. 2012. Functional polymorphism of the dopamine β-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. J Clin Psychopharmacol. 32:578–580.
   Google Scholar
• Mutschler J, Eifler S, Dirican G, Grosshans M, Kiefer F, Rossler W, Diehl A. 2013. Functional social support within a medical supervised outpatient treatment programme. Am J Drug Alcohol Abuse. 39:44–49.
   Google Scholar
• Myrick H, Malcolm R, Brady KT. 1998. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 155:1632
   Google Scholar
• Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL. 2009. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 33:1582–1588.
   Google Scholar
• N’Gouemo P, Akinfiresoya LR, Allard JS, Lovinger DM. 2015. Alcohol withdrawal-induced seizure susceptibility is associated with an upregulation of Cav1.3 channels in the rat inferior colliculus. J Neuropsychopharmacol. 18:pyu123.
   Google Scholar
• N’Gouemo P, Yasuda R, Faingold CL. 2010. Seizure susceptibilty is associated with altered protein expression of volatge-agted calcium channel subunits in inferior colliculus neurons of the genetically epilepsy-prone rat. Brain Res. 1308:153–157.
   Google Scholar
• Nguyen SA, Malcolm R, Middaugh LD. 2007. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse. 61:150–156.
   Google Scholar
• NICE. 2011. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. Available from: https://www.nice.org.uk/guidance/cg115
   Google Scholar
• Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM. 2002. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 37:67–73.
   Google Scholar
• Nocente R, Vitali M, Balducci G, Enea D, Kranzler HR, Ceccanti M. 2013. Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction? Am J Addict. 22:453–459.
   Google Scholar
• Noordsy DL, O'Keefe C, Mueser KT, Xie H. 2001. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv. 52:501–507.
   Google Scholar
• Noronha ABC, Cui C, Harris RA, Crabbe JC. 2014. Neurobiology of alcohol dependence. London, Waltham (San Diego): Academic Press.
   Google Scholar
• Ntais C, Pakos E, Kyzas P, Ioannidis JP. 2005. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. CD005063.
   Google Scholar
• Nunes EV, Levin FR. 2004. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 291:1887–1896.
   Google Scholar
• Nutt D, Nestor L. 2013. Addiction. Kettering: Oxford University Press.
   Google Scholar
• Nutt DJ. 2014. The role of the opioid system in alcohol dependence. J Psychopharmacol (Oxford). 28:8–22.
   Google Scholar
• O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. 2007. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 27:507–512.
   Google Scholar
• O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B. 1996a. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry. 53:217–224.
   Google Scholar
• O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ. 1996b. Experience of a “slip” among alcoholics treated with naltrexone or placebo. Am J Psychiatry. 153:281–283.
   Google Scholar
• Odlaug BL, Gual A, DeCourcy J, Perry R, Pike J, Heron L, Rehm J. 2016. Alcohol dependence, co-occurring conditions and attributable burden. Alcohol Alcohol. 51:201–209.
   Google Scholar
• Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O’Brien CP. 2003. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 28:1546–1552.
   Google Scholar
• Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M. 2015. Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA Psychiatry. 72:430–437.
   Google Scholar
• Oswald LM, Wand GS. 2004. Opioids and alcoholism. Physiol Behav. 81:339–358.
   Google Scholar
• Pani PP, Trogu E, Pacini M, Maremmani I. 2014. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2:CD008544.
   Google Scholar
• Pastor A, Lloyd-Jones M, Currie J. 2013. Reply to Dr Rolland et al. re: “Baclofen for alcohol-dependence: anticraving or partial substitution?”. J Clin Psychopharmacol. 33:281–282.
   Google Scholar
• Petrakis IL. 2006. A rational approach to the pharmacotherapy of alcohol dependence. J Clin Psychopharmacol. 26(Suppl 1):S3–S12.
   Google Scholar
• Petrakis IL, Nich C, Ralevski E. 2006. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophrenia Bull. 32:644–654.
   Google Scholar
• Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP. 2010. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 167:668–675.
   Google Scholar
• Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. 2001. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 21:143–153.
   Google Scholar
• Pirkola SP, Poikolainen K, Lonnqvist JK. 2006. Currently active and remitted alcohol dependence in a nationwide adult general population–results from the Finnish Health 2000 study. Alcohol Alcohol. 41:315–320.
   Google Scholar
• Plebani JG, Lynch KG, Rennert L, Pettinati HM, O'Brien CP, Kampman KM. 2013. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend. 133:754–758.
   Google Scholar
• Potvin S, Pampoulova T, Mancini-Marie A, Lipp O, Bouchard RH, Stip E. 2006. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry. 77:796–798.
   Google Scholar
• Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, Brady KT, Davidson JR. 2001. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 14:255–262.
   Google Scholar
• Rapinesi C, Kotzalidis GD, Scatena P, Del Casale A, Janiri D, Callovini G, Piacentino D, Serata D, Raccah RN, Brugnoli R, et al. 2014. Alcohol and suicidality: could deep transcranial magnetic stimulation (dTMS) be a possible treatment? Psychiatria Danubina. 26:281–284.
   Google Scholar
• Ray LA, Heydari A, Zorick T. 2010. Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev. 29:568–575.
   Google Scholar
• Ray LA, Miranda R, Jr., MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, Gwaltney C, Swift RW, Monti PM. 2009. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 17:122–129.
   Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. 1990. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 264:2511–2518.
   Google Scholar
• Rehm J, Allamani A, Elekes Z, Jakubczyk A, Manthey J, Probst C, Struzzo P, Della Vedova R, Gual A, Woinar M. 2015. Alcohol dependence and treatment utilization in Europe: a representative cross-sectional study in primary care. BMC Fam Prac. 16:90.
   Google Scholar
• Rehm J, Baliunas D, Borges GL, Graham K, Irving H, Kehoe T, Parry CD, Patra J, Popova S, Poznyak V, et al. 2010. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 105:817–843.
   Google Scholar
• Rehm J, Room R, van den Brink W, Jacobi F. 2005. Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol. 15:377–388.
   Google Scholar
• Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. 2001. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 25:1324–1329.
   Google Scholar
• Riper H, Andersson G, Hunter SB, de Wit J, Berking M, Cuijpers P. 2014. Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis. Addiction. 109:394–406.
   Google Scholar
• Ritola E, Malinen L. 1981. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatrica Scand. 64:254–259.
   Google Scholar
• Roerecke M, Rehm J. 2013. Alcohol use disorders and mortality: a systematic review and meta-analysis. Addiction. 108:1562–1578.
   Google Scholar
• Roerecke M, Rehm J. 2014. Alcohol consumption, drinking patterns, and ischaemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. BMC Med. 12:182.
   Google Scholar
• Rolland B, Bordet R, Cottencin O. 2012. Alcohol-dependence: the current French craze for baclofen. Addiction. 107:848–849.
   Google Scholar
• Rolland B, Bordet R, Deheul S, Cottencin O. 2013. Baclofen for alcohol-dependence: anticraving or partial substitution? J Clin Psychopharmacol. 33:280–281.
   Google Scholar
• Rolland B, Labreuche J, Duhamel A, Deheul S, Gautier S, Auffret M, Pignon B, Valin T, Bordet R, Cottencin O. 2015. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 25:1631–1636.
   Google Scholar
• Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, Dematteis M, Mann K, Aubin HJ. 2016. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the french alcohol society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 22:25–37.
   Google Scholar
• Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. 2010a. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 9:CD004332.
   Google Scholar
• Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. 2010b. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 12:CD001867.
   Google Scholar
• Rustembegovic A, Sofic E, Kroyer G. 2002. A pilot study of topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Medicinski Arhiv. 56:211–212.
   Google Scholar
• Rustembegovic A, Sofic E, Tahirovic I, Kundurovic Z. 2004. A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome. Medicinski Arhiv. 58:5–6.
   Google Scholar
• Sachdeva A, Chandra M, Deshpande SN. 2014. A comparative study of fixed tapering dose regimen versus symptom-triggered regimen of lorazepam for alcohol detoxification. Alcohol Alcohol. 49:287–291.
   Google Scholar
• Sachdeva A, Choudhary M, Chandra M. 2015. Alcohol withdrawal syndrome: benzodiazepines and beyond. J Clin Diagn Res. 9:VE01–VE07.
   Google Scholar
• Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. 2005. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 62:37–45.
   Google Scholar
• Sarai M, Tejani AM, Chan AH, Kuo IF, Li J. 2013. Magnesium for alcohol withdrawal. Cochrane Database Syst Rev. 6:CD008358.
   Google Scholar
• Sass H, Soyka M, Mann K, Zieglgansberger W. 1996. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 53:673–680.
   Google Scholar
• Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B. 2012. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila). 50:458–470.
   Google Scholar
• Schmidt CS, Schulte B, Seo HN, Kuhn S, A OD, Kriston L, Verthein U, Reimer J. 2015. Meta-analysis on the effectiveness of alcohol screening with brief interventions for patients in emergency care settings. Addiction. 111:783–794.
   Google Scholar
• Schoepf D, Heun R. 2015. Alcohol dependence and physical comorbidity: Increased prevalence but reduced relevance of individual comorbidities for hospital-based mortality during a 12.5-year observation period in general hospital admissions in urban North-West England. Eur Psychiatry. 30:459–468.
   Google Scholar
• Schuckit MA, Tipp JE, Bergman M, Reich W, Hesselbrock VM, Smith TL. 1997. Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am J Psychiatry. 154:948–957.
   Google Scholar
• Schumann G, Spanagel R, Mann K. 2003. Candidate genes for alcohol dependence: animal studies. Alcohol Clin Exp Res. 27:880–888.
   Google Scholar
• Seifert J, Peters E, Jahn K, Metzner C, Ohlmeier M, te Wildt B, Emrich HM, Schneider U. 2004. Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance-a pilot study. Addict Biol. 9:43–51.
   Google Scholar
• Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K. 1983. Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther. 34:822–826.
   Google Scholar
• Shaw JM, Kolesar GS, Sellers EM, Kaplan HL, Sandor P. 1981. Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol. 1:382–389.
   Google Scholar
• Shekelle PG, Woolf SH, Eccles M, Grimshaw J. 1999. Clinical guidelines: developing guidelines. BMJ. 318:593–596.
   Google Scholar
• Siris SG. 1990. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophrenia Bull. 16:111–122.
   Google Scholar
• Skinner MD, Lahmek P, Pham H, Aubin HJ. 2014. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 9:e87366.
   Google Scholar
• Skradski S, White HS. 2000. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 41(Suppl 1):S45–S47.
   Google Scholar
• Smedslund G, Berg RC, Hammerstrom KT, Steiro A, Leiknes KA, Dahl HM, Karlsen K. 2011. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 5:CD008063.
   Google Scholar
• Soyka M. 1990. Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia. Acta Psychiatr Scand. 81:255–259.
   Google Scholar
• Soyka M. 2016. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 17:619–626.
   Google Scholar
• Soyka M, Albus M, Kathmann N, Finelli A, Hofstetter S, Holzbach R, Immler B, Sand P. 1993. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 242:362–372.
   Google Scholar
• Soyka M, Botschev C, Volcker A. 1992. Neuroleptic treatment in alcohol hallucinosis-no evidence for increased seizure risk. J Clin Psychopharmacol. 12:66–67.
   Google Scholar
• Soyka M, Friede M, Schnitker J. 2016. Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis. Pharmacopsychiatry. 49:66–75.
   Google Scholar
• Soyka M, Koch W, Tatsch K. 2005. Thalamic hypofunction in alcohol hallucinosis: FDG PET findings. Psychiatry Res. 139:259–262.
   Google Scholar
• Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF. ACTOL Study Investigators. 2008a. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol. 28:317–324.
   Google Scholar
• Soyka M, Lieb M. 2015. Recent developments in pharmacotherapy of alcoholism. Pharmacopsychiatry. 48:123–135.
   Google Scholar
• Soyka M, Morhart-Klute V, Horak M. 2002. A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study. Eur Arch Psychiatry Clin Neurosci. 252:197–200.
   Google Scholar
• Soyka M, Preuss UW, Hesselbrock V, Zill P, Koller G, Bondy B. 2008b. GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. J Psychiatric Res. 42:184–191.
   Google Scholar
• Soyka M, Roesner S. 2006. New pharmacological approaches for the treatment of alcoholism. Expert Opin Pharmacother. 7:2341–2353.
   Google Scholar
• Soyka M, Schmidt F, Schmidt P. 2006. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry. 39:30–34.
   Google Scholar
• Spanagel R. 2009. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 89:649–705.
   Google Scholar
• Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, Lascorz J, Depner M, Holzberg D, Soyka M, et al. 2005. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nature Med. 11:35–42.
   Google Scholar
• Spanagel R, Vengeliene V. 2013. New pharmacological treatment strategies for relapse prevention. Curr Topics Behav Neurosci. 13:583–609.
   Google Scholar
• Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F. 2014. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacol. 39:783–791.
   Google Scholar
• Spanagel R, Weiss F. 1999. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22:521–527.
   Google Scholar
• Spanagel R, Zieglgansberger W. 1997. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 18:54–59.
   Google Scholar
• Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. 2010. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res. 34:1822–1831.
   Google Scholar
• Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW. 1992. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 27:153–158.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. 1999. Brief interventions in substance abuse treatment. In: Brief interventions and brief therapies for substance abuse: TIP 34. Rockville (MD): US Department of Health and Human Services.
   Google Scholar
• Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. 2006. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 26:290–302.
   Google Scholar
• Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. 1989. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 84:1353–1357.
   Google Scholar
• Sullivan LE, Fiellin DA, O'Connor PG. 2005. The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med. 118:330–341.
   Google Scholar
• Svanberg J, Evans JJ. 2013. Neuropsychological rehabilitation in alcohol-related brain damage: a systematic review. Alcohol Alcohol. 48:704–711.
   Google Scholar
• Thompson MD, Kenna GA. 2016. Variation in the serotonin transporter gene and alcoholism: Risk and response to pharmacotherapy. Alcohol Alcohol. 51:164–171.
   Google Scholar
• Thomson AD, Cook CC, Touquet R, Henry JA. 2002. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department. Alcohol Alcohol. 37:513–521.
   Google Scholar
• Torrens M, Fonseca F, Mateu G, Farre M. 2005. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 78:1–22.
   Google Scholar
• Tsuang JW, Irwin MR, Smith TL, Schuckit MA. 1994. Characteristics of men with alcoholic hallucinosis. Addiction. 89:73–78.
   Google Scholar
• Ungur LA, Neuner B, John S, Wernecke K, Spies C. 2013. Prevention and therapy of alcohol withdrawal on intensive care units: systematic review of controlled trials. Alcohol Clin Exp Res. 37:675–686.
   Google Scholar
• Vaillant GE. 1996. A long-term follow-up of male alcohol abuse. Arch Gen Psychiatry. 53:243–249.
   Google Scholar
• van den Brink W, Aubin HJ, Bladstrom A, Torup L, Gual A, Mann K. 2013. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 48:570–578.
   Google Scholar
• van den Brink W, Sorensen P, Torup L, Mann K, Gual A. 2014. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. J Psychopharmacol (Oxford). 28:733–744.
   Google Scholar
• Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. 1995. Effect of naltrexone on alcohol “ high” in alcoholics. Am J Psychiatry. 152:613–615.
   Google Scholar
• Voris J, Smith NL, Rao SM, Thorne DL, Flowers QJ. 2003. Gabapentin for the treatment of ethanol withdrawal. Substance Abuse. 24:129–132.
   Google Scholar
• Walker BM, Koob GF. 2008. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.Neuropsychopharmacology. 33:643–652.
   Google Scholar
• Walker BM, Valdez GR, McLaughlin JP, Bakalkin G. 2012. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol. 46:359–370.
   Google Scholar
• Walker BM, Zorrilla EP, Koob GF. 2011. Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict Biol. 16:116–119.
   Google Scholar
• Watson WP, Robinson E, Little HJ. 1997. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology. 36:1369–1375.
   Google Scholar
• Weiss F, Porrino LJ. 2002. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci. 22:3332–3337.
   Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, et al. 2013. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 382:1575–1586.
   Google Scholar
• Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. 2015. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 10:e0116820.
   Google Scholar
• Whitfield CL, Thompson G, Lamb A, Spencer V, Pfeifer M, Browning-Ferrando M. 1978. Detoxification of 1,024 alcoholic patients without psychoactive drugs. JAMA. 239:1409–1410.
   Google Scholar
• Wong A, Benedict NJ, Lohr BR, Pizon AF, Kane-Gill SL. 2015. Management of benzodiazepine-resistant alcohol withdrawal across a healthcare system: Benzodiazepine dose-escalation with or without propofol. Drug Alcohol Depend. 154:296–299.
   Google Scholar
• Youland KM, Miller RF, Mahonen CJ, Borgers AJ, Gundrum JD. 2014. Leviracetam as adjunctive therapy for acute alcohol withdrawal syndrome in hospitalized patients. J Clin Psychopharmacol. 34:704–708.
   Google Scholar